Free tool
FAERS Monitor: Edurant Ped
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219016 or its brand name (Edurant Ped, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
55
Serious
52
95% of reports
Hospitalization
15
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- depressed mood4
- drug interaction4
- insomnia4
- off label use4
- rash4
- abnormal dreams3
- acute kidney injury3
- confusional state3
- depression3
- disorientation3
- fatigue3
- haemoglobin decreased3
- hallucination3
- hepatotoxicity3
- hyperuricaemia3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperuricaemiaSignal | 3 | 279.3 | 92.9 | 577 |
| hepatotoxicitySignal | 3 | 51.5 | 17.1 | 103 |
| abnormal dreamsSignal | 3 | 41.6 | 13.8 | 82 |
| disorientationSignal | 3 | 29.0 | 9.6 | 56 |
| depressed moodSignal | 4 | 28.9 | 11.3 | 82 |
| hallucinationSignal | 3 | 15.2 | 5.1 | 27 |
| haemoglobin decreasedSignal | 3 | 11.2 | 3.7 | 19 |
| drug interactionSignal | 4 | 9.6 | 3.8 | 23 |
| acute kidney injurySignal | 3 | 7.5 | 2.5 | 11 |
| confusional stateSignal | 3 | 7.1 | 2.4 | 10 |
| insomniaSignal | 4 | 5.7 | 2.2 | 11 |
| depressionSignal | 3 | 5.0 | 1.7 | 6 |
| rashSignal | 4 | 3.5 | 1.4 | 5 |
| off label use | 4 | 1.7 | 0.7 | 1 |
| fatigue | 3 | 1.5 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.